Suppr超能文献

[肝硬化患者难治性腹水的治疗现状]

[Current status of treatment of refractory ascites in patients with liver cirrhosis].

作者信息

Shao J, Zhang L, Han G H, Fan D M

机构信息

Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of the Fourth Military Medical University, Xi'an 710032, China.

出版信息

Zhonghua Gan Zang Bing Za Zhi. 2016 Oct 20;24(10):721-723. doi: 10.3760/cma.j.issn.1007-3418.2016.10.001.

Abstract

Ascites is a common clinical manifestation of cirrhotic portal hypertension, and about 60%-80% of cirrhotic patients develop the symptom of ascites within 10 years. Once ascites occurs, the 5-year survival rate is reduced from 80% to 50%. With the progression of liver diseases, approximately 5%-10% of patients with ascites develop refractory ascites, and the median survival time is only 6-12 months. This article reviews the definition and diagnosis of refractory ascites, evaluation of prognostic factors, and treatment regimens, including large-volume paracentesis combined with protein supplementation, transjugular intrahepatic portosystemic shunt, and liver transplantation.

摘要

腹水是肝硬化门静脉高压的常见临床表现,约60%-80%的肝硬化患者在10年内会出现腹水症状。一旦出现腹水,5年生存率会从80%降至50%。随着肝脏疾病的进展,约5%-10%的腹水患者会发展为难治性腹水,中位生存时间仅为6-12个月。本文综述了难治性腹水的定义与诊断、预后因素评估以及治疗方案,包括大量腹腔穿刺放液联合补充蛋白、经颈静脉肝内门体分流术和肝移植。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验